Transplant Trial Watch

Remnant cholesterol is prospectively associated with CVD events and all-cause mortality in kidney transplant recipients: the FAVORIT study.

Horace, R. W., et al.

Nephrology Dialysis Transplantation 2021 [record in progress].

This study aimed to determine whether remnant cholesterol is associated with the risk of cardiovascular (CVD) events among kidney transplant patients from the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) trial.

Participants in the FAVORIT trial were randomly assigned to receive either a standard multivitamin containing high doses of folic acid, vitamin B6 and B12, or a multivitamin with low doses of vitamin B6 and B12 and no folic acid.

3812 kidney transplant patients were included in the analysis.

The primary endpoint was the assessment of the link between remnant cholesterol and the risk of CVD events. The secondary outcomes included the assessment of the relationship of remnant cholesterol with renal graft failure, mortality (all causes) and CVD events.

4 years

CET Conclusions
This is a subgroup analysis of the FAVORIT trial, which compared a combination of high dose folic acid, and vitamins B12 and B6 with low dose vitamins B12 and B6 in stable renal transplant recipients with elevated total homocysteine levels. The subgroup analysis aimed to determine the association of remnant cholesterol and the risk of cardiovascular disease events in 3812 stable kidney transplant recipients with remnant cholesterol. Data were collected over a mean follow up of four years (SD 1.5 years) and showed an increased risk of CVD events and all-cause mortality in patients with higher levels of remnant cholesterol. There was no increased risk of impaired kidney function.

Trial registration

Funding source
Non-industry funded